
Topic
Clinical Evidence
Trial design, endpoints, real-world evidence, safety updates, and how evidence translates into market access.

Pricing & Access· May 31, 2026 · 10 min read

Pipeline· May 31, 2026 · 8 min read
Tebipenem HBr PDUFA preview for oral carbapenem access
By Ran Chen#PDUFA Date#FDA Approval#Infectious Disease

Pipeline· May 31, 2026 · 10 min read
Veligrotug vs Tepezza thyroid eye disease access guide
By Ran Chen#PDUFA Date#FDA Approval#Ophthalmology

Pipeline· May 27, 2026 · 7 min read
Antibody-drug conjugate access landscape: ADC coverage and pipeline watch
By Ran Chen#ADC#HER2#Prior Authorization

Pipeline· May 27, 2026 · 7 min read
ASCO 2026 pipeline evidence preview for formulary and access teams

Pricing & Access· May 27, 2026 · 11 min read
Keytruda Qlex vs IV Keytruda access guide

Pricing & Access· May 27, 2026 · 11 min read
Tepezza coverage guide for thyroid eye disease access

Pipeline· May 26, 2026 · 8 min read
CagriSema pre-approval evidence review for obesity access teams
By Ran Chen#GLP-1#Amylin Analog#Obesity

Approvals· May 26, 2026 · 8 min read
Novel FDA drug approvals Q1-Q2 2026: the fifteen drugs and their formulary implications
By Ran Chen#FDA Approval#Novel Drug Approvals#GLP-1

Approvals· May 25, 2026 · 8 min read